Prostate Cell News Volume 10.16 | May 10 2019

TOP STORY

KMT9 Monomethylates Histone H4 Lysine 12 and Controls Proliferation of Prostate Cancer Cells

Scientists revealed enrichment for lysine methyltransferase 9 (KMT9) and lysine 12 of histone H4 me1 at the promoters of numerous genes encoding cell cycle regulators and control of cell cycle progression by KMT9. Importantly, KMT9 depletion severely affected the proliferation of androgen receptor-dependent, as well as that of castration- and enzalutamide-resistant prostate cancer cells and xenograft tumors. [Nat Struct Mol Biol] Abstract

(Ranked by impact factor of the journal)

PGC-1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

Researchers showed that peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) repressed the metastatic properties of prostate cancer cells via modulation of the polyamine biosynthesis pathway. Mechanistically, PGC-1α inhibited the expression of c-MYC and ornithine decarboxylase 1, the rate limiting enzyme for polyamine synthesis. [Cancer Res] Abstract

Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Non-Steroidogenic Cholesterol Metabolism in Prostate Cancer

In androgen-responsive castration-resistant prostate cancer cell model C4-2, scavenger receptor B1 (SR-B1) antagonism suppressed cholesterol uptake, de novo steroidogenesis, and androgen receptor activity. SR-B1 antagonism also suppressed growth and viability and induced endoplasmic reticulum stress and autophagy. [Cancer Res] Abstract

Alginate Oligosaccharide Attenuates α2,6-Sialylation Modification to Inhibit Prostate Cancer Cell Growth via the Hippo/YAP Pathway

The authors showed that alginate oligosaccharide (AOS) inhibited cell growth, which was consistent with the attenuation of α2,6-sialylation modification. Furthermore, AOS inhibited ST6Gal-1 promoter activity and thus affected transcriptional processes. [Cell Death Dis] Full Article

Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer

Investigators showed that the androgen receptor (AR), a key oncogene in prostate cancer, controlled multiple isocitrate dehydrogenase (IDH) isoforms in both in vitro and in vivo models, predominantly positively regulating IDH1. Chromatin immunoprecipitation experiments confirmed the recruitment of AR at several regulatory regions of IDH1 and enzymatic assays demonstrated that AR significantly induces IDH activity. [Mol Cancer Res] Abstract

Downregulation of RalGTPase-Activating Protein Promotes Invasion of Prostatic Epithelial Cells and Progression from Intraepithelial Neoplasia to Cancer during Prostate Carcinogenesis

Silencing of RalGTPase-activating protein (RalGAP)-2 by shRNA enhanced migration and invasion abilities of benign and malignant prostate epithelial cell lines without affecting cell proliferation. Exogenous expression of wild-type RalGAP, but not the GAP activity-deficient mutant of RalGAP, suppressed migration and invasion of multiple prostate cancer cell lines and was phenocopied by pharmacological inhibition of RalA/B. [Carcinogenesis] Abstract

Interleukin-7 Contributes to the Invasiveness of Prostate Cancer Cells by Promoting Epithelial-Mesenchymal Transition

Scientists found that interleukin-7 (IL-7) stimulated wound-healing migration and invasion of PC-3 cells, increased phosphorylation of signal transducer and activator of transcription 5, Akt, and extracellular signal-regulated kinase. On the other hand, a JAK inhibitor and an IL-7-blocking antibody decreased the invasiveness of PC-3 cells. [Sci Rep] Full Article

Glycidamide Promotes the Growth and Migratory Ability of Prostate Cancer Cells by Changing the Protein Expression of Cell Cycle Regulators and Epithelial-to-Mesenchymal Transition (EMT)-Associated Proteins with Prognostic Relevance

Researchers demonstrated that glycidamide (GA) promoted the growth of prostate cancer cells through induced protein expression of the cell cycle regulator. In addition, they also found that GA promoted the migratory ability of prostate cancer cells through induced EMT-associated protein expression. [Int J Mol Sci] Full Article

High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line

Investigators concluded that boric acid caused oxidative stress, inhibition of cell growth, apoptosis, and morphological alterations in a concentration-dependent manner in DU-145 cells. Furthermore, treatments with increasing boric acid concentrations decreased the antioxidant levels in cells. [Biol Trace Elem Res] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Interplay between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

The authors discuss the critical role of SOX9/AR/Wnt/β-catenin signaling axis in the development and progression of castration-resistant prostate cancer (Pca). The phytochemicals like sulforaphane and curcumin that can concurrently target SOX9, AR and Wnt/β-catenin signaling pathways in PCa may thus be beneficial in the chemoprevention of PCa. [Int J Mol Sci] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Cotinga Pharmaceuticals Releases Early Interim Data of Phase Ib/IIa Combination Trial of COTI-2 in Solid Tumors

Cotinga Pharmaceuticals Inc. announced that the company has released early interim data of its ongoing Phase Ib/IIa clinical trial of COTI-2 plus cisplatin in solid tumors. The primary objective of the second cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin. Secondary objectives include determination of efficacy and pharmacokinetics profiling. [Cotinga Pharmaceuticals Inc. (GlobeNewswire, Inc.)] Press Release

Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase Ib Clinical Trial of AsiDNA™ in Combination with Chemotherapy

Onxeo S.A. announced a new milestone in the clinical development of AsiDNA™ with the treatment of the first patient in DRIIV-1b, a Phase Ib clinical study of AsiDNA™, a first-in-class tumor DNA repair inhibitor, in combination with carboplatin and with carboplatin plus paclitaxel, in patients with solid tumors eligible to such treatments. [Onxeo S.A.] Press Release

HedgePath Pharmaceuticals Announces Notice of Allowability of US Patent Application Regarding Treatment of Prostate Cancer

HedgePath Pharmaceuticals, Inc. announced that the US Patent & Trademark Office has notified HedgePath that new claims have been allowed regarding the use of the anti-fungal drug itraconazole, and specifically the patented formulation of SUBA-Itraconazole in patients with prostate cancer. [HedgePath Pharmaceuticals, Inc.] Press Release

Academics Raise Concerns About Predatory Journals on PubMed

The National Library of Medicine has quality control procedures in place, but some researchers believe additional scrutiny is necessary. [The Scientist] Editorial

Intolerance and Funding Concern Indian Scientists Ahead of Election

A rising intolerance towards intellectuals and minority groups in India has prompted scientists there to speak out ahead of the country’s mammoth general election. More than 200 scientists have signed an open letter appealing to citizens to reject the discrimination and violence being promoted by some extremist groups. [Nature News] Editorial

Brazilian Biomedical Science Faces Reproducibility Test

An ambitious project to test the reproducibility of biomedical experiments by Brazilian scientists is about to get under way. The Brazilian Reproducibility Initiative was launched last year by researchers at the Federal University of Rio de Janeiro. Now, the first wave of reproducibility testing is set to begin in August, with help from more than 60 laboratories scattered over 43 Brazilian research centers. [Nature News] Editorial

US Lawmakers Propose Plan to Reduce Primate Research at National Institutes of Health

The US National Institutes of Health (NIH) would be required to reduce its use of non-human primates in research, under a spending bill approved on 8 May by a committee in the US House of Representatives. The bill would direct the NIH “to accelerate efforts to reduce and replace the use of nonhuman primates with alternative research models” in its laboratories. [Nature News] Editorial

NEW Keystone Symposia: Tumor Metabolism
March 8-12, 2020
Banff, Alberta, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Cancer Cell Biology (University of Zurich)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK)

Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University)

Postdoctoral Research Fellow – Mechanisms of Prostate Cancer Resistance (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland)

Postdoctoral Fellow – Cancer Systems Imaging (The University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow and PhD Student Position – Hormone Driven Cancer (Institute of Oncology Research)

Postdoctoral Position – Prostate Cancer (UT Health San Antonio)

Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.